3rd Quarter - Report

AVENUE SOLUTIONS for CUBIST PHARMACEUTICALS, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 1734 / H.R. 2182, Generating Antiobiotic Incentives Now Act (GAIN Act) - incentives for development of products to treat antibiotic-resistant infections; S. 3187, Food and Drug Administration Safety and Innovation Act - incentives for development of products to treat antibiotic-resistant infections; H.R. 5651, Food and Drug Administration Reform Act of 2012 - incentives for development of products to treat antibiotic-resistant infections

LobbyistCovered position, as disclosed
ELIZABETH MACDONALD BARNETT —
TRACY SPICER —
AMY TEJRAL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5651 (112th), S. 1734 (112th), S. 3187 (112th), H.R. 2182 (112th)

Pharmacy PHA

S. 1734 / H.R. 2182, Generating Antiobiotic Incentives Now Act (GAIN Act) - incentives for development of products to treat antibiotic-resistant infections; S. 3187, Food and Drug Administration Safety and Innovation Act - incentives for development of products to treat antibiotic-resistant infections; H.R. 5651, Food and Drug Administration Reform Act of 2012 - incentives for development of products to treat antibiotic-resistant infections

LobbyistCovered position, as disclosed
ELIZABETH MACDONALD BARNETT —
TRACY SPICER —
AMY TEJRAL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1734 (112th), H.R. 5651 (112th), S. 3187 (112th), H.R. 2182 (112th)

Budget/Appropriations BUD

Impact of sequestration on FDA user fees

LobbyistCovered position, as disclosed
ELIZABETH MACDONALD BARNETT —
TRACY SPICER —
AMY TEJRAL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.